10/13/05

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1612RXD

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	JUL 20	Powerful new interactive analysis and visualization software, STN AnaVist, now available
NEWS	4	AUG 11	STN AnaVist workshops to be held in North America
NEWS	5	AUG 30	CA/CAplus -Increased access to 19th century research documents
NEWS	6	AUG 30	CASREACT - Enhanced with displayable reaction conditions
NEWS	7	SEP 09	ACD predicted properties enhanced in REGISTRY/ZREGISTRY
NEWS	8	OCT 03	MATHDI removed from STN
NEWS	9	OCT 04	CA/CAplus-Canadian Intellectual Property Office (CIPO) added to core patent offices
NEWS	10	OCT 06	STN AnaVist workshops to be held in North America
NEWS	11	OCT 13	New CAS Information Use Policies Effective October 17, 2005

NEWS EXPRESS JUNE 13 CURRENT WINDOWS VERSION IS V8.0, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 13 JUNE 2005

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 16:30:39 ON 13 OCT 2005

=> file registry

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 16:30:51 ON 13 OCT 2005

10805222

10/13/05

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 12 OCT 2005 HIGHEST RN 865114-63-2
DICTIONARY FILE UPDATES: 12 OCT 2005 HIGHEST RN 865114-63-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

****
* *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
* *
****

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10805222.str

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

10805222

10/13/05

```
=> s l1
SAMPLE SEARCH INITIATED 16:31:17 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -       158 TO ITERATE

100.0% PROCESSED      158 ITERATIONS                                  0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:          2406 TO     3914
PROJECTED ANSWERS:                0 TO        0

L2            0 SEA SSS SAM L1

=> s l1 ful
FULL SEARCH INITIATED 16:31:22 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      3593 TO ITERATE

100.0% PROCESSED     3593 ITERATIONS                                  0 ANSWERS
SEARCH TIME: 00.00.01

L3            0 SEA SSS FUL L1

=>
Uploading C:\Program Files\Stnexp\Queries\10805222.str

L4      STRUCTURE UPLOADED

=> d l4
L4 HAS NO ANSWERS
L4                STR
```




```
Structure attributes must be viewed using STN Express query preparation.


=>  s l4
SAMPLE SEARCH INITIATED 16:32:28 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -       40 TO ITERATE

100.0% PROCESSED       40 ITERATIONS                                  0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
```

10/13/05

PROJECTED ITERATIONS: 421 TO 1179
PROJECTED ANSWERS: 0 TO 0

L5 0 SEA SSS SAM L4

=> s l4 ful
FULL SEARCH INITIATED 16:32:33 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 988 TO ITERATE

100.0% PROCESSED 988 ITERATIONS 15 ANSWERS
SEARCH TIME: 00.00.02

L6 15 SEA SSS FUL L4

=> file caplus
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	323.09	323.30

FILE 'CAPLUS' ENTERED AT 16:32:38 ON 13 OCT 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 13 Oct 2005 VOL 143 ISS 16
FILE LAST UPDATED: 12 Oct 2005 (20051012/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l6
L7 5 L6

=> d abs bib hitstr 1-5

L7 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN
GI



I

AB Title compds. [I; X = (CH2)x; Y = (CH2)y; Z = (CH2)z; x, y, z = 0-4; Q = O, H2; R (sic) = H, (substituted) alkyl, aryl, heterocyclyl], were prepared Thus, title compound I (X, Y, Z = CH2; Q = O), prepared by solid phase synthesis, was active in rats at 0.3 mg/kg orally in the forced swimming test and the light/dark box test.

AN 2005:1028083 CAPLUS

TI Preparation of tetrahydro-β-carbolines for treatment of neurological disease.

IN Burns, Mark R.

PA Mediquest Therapeutics, Inc., USA

SO U.S. Pat. Appl. Publ., 18 pp.
CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2005209264	A1	20050922	US 2004-805222	20040322
WO 2005092335	A1	20051006	WO 2005-US9360	20050322

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2004-805222 A 20040322

IT **864951-47-3P 864951-48-4P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(claimed compound; preparation of tetrahydro-β-carbolines for treatment of neurol. disease)

RN 864951-47-3 CAPLUS

CN INDEX NAME NOT YET ASSIGNED



RN 864951-48-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



IT **864951-49-5P 864951-50-8P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of tetrahydro-β-carbolines for treatment of neurol. disease)
RN 864951-49-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.





RN 864951-50-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.

applied PD 3/22/2004.



●5 HCl

L7 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN

AB The invention relates to conjugates of peptides related to the sequence Ala-Arg-Pro-Ala-Lys (P6A) with (S)-1,2,3,4-tetrahydro-β-carboline-3-carboxylic acid for use as thrombolytic agents. Thus, 3S-1,2,3,4-tetrahydro-β-carboline-3-carboxyl-Ala-Arg-Pro-Ala-Lys-OH (11) was prepared by coupling of H-Ala-Arg(Tos)-Pro-Ala-Lys(ClZ)-OBzl.HCl (Tos = tosyl, ClZ = chlorobenzyloxycarbonyl; preparation given) with (S)-2-Boc-1,2,3,4-tetrahydro-β-carboline-3-carboxylic acid (Boc = tert-butoxycarbonyl), followed by deprotection with HF. Pseudopeptide 11 was assayed for thrombolytic activity in rats, showing a reduction in thrombolytic mass (x) of 14.01 ± 2.61 mg (vs. x = 18.844 ± 3.18 mg for P6A).

AN 2005:325686 CAPLUS
DN 142:374115

TI Preparation of carboline-3-carboxylic acid conjugates with peptide sequences related to Ala-Arg-Pro-Ala-Lys and their use as thrombolytic agent

IN Peng, Shiqi; Zhao, Ming; Wang, Chao; Wu, Yangfen
PA Peop. Rep. China

SO U.S. Pat. Appl. Publ., 29 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2005080015	A1	20050414	US 2003-680293	20031008
PRAI US 2003-680293		20031008		

IT **666832-04-8P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of peptide-tetrahydrocarbolinecarboxylic acid conjugates as thrombolytic agents)

RN 666832-04-8 CAPLUS

CN L-Lysine, (3S)-2-[(1,1-dimethylethoxy)carbonyl]-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carbonyl-L-prolyl-L-alanyl-N6-[[(2-chlorophenyl)methoxy]carbonyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



IT **666832-21-9P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of peptide-tetrahydrocarbolinecarboxylic acid conjugates as thrombolytic agents)
RN 666832-21-9 CAPLUS
CN L-Lysine, (3S)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carbonyl-L-prolyl-L-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN

AB From the metabolism of H-Ala-Arg-Pro-Ala-Lys-OH, four metabolites, H-Pro-Ala-Lys-OH, H-Arg-Pro-Ala-Lys-OH, H-Ala-Arg-Pro-OH, and H-Ala-Arg-Pro-Ala-OH were identified. In order to find a new lead compound of thrombolytic peptide, 3S-1,2,3,4-tetrahydro-β-carboline-3-carboxylic acid was introduced to the N- and C-terminal of the metabolites by use of the common coupling strategy. Under this condition, the pseudopeptides were obtained with a good yield. The thrombolytic activities of 3S-1,2,3,4-tetrahydro-β-carboline-3-carboxylic acid containing oligopeptides were evaluated in vitro and in vivo. The result indicated that the thrombolytic activity of the pseudopeptide depended on the sequence and the modification pattern of the metabolites, and only when 3S-1,2,3,4-tetrahydro-β-carboline-3-carboxylic acid was introduced into the C-terminal of H-Pro-Ala-Lys-OH or H-Arg-Pro-Ala-Lys-OH, the desirable thrombolytic activity was retained and enhanced significantly.

AN 2004:114609 CAPLUS
DN 141:81672

TI Synthesis and Thrombolytic Activity of Carboline-3-carboxylic Acid Modified Metabolites of Ala-Arg-Pro-Ala-Lys

AU Zhao, Ming; Wang, Chao; Wu, Yanfen; Zhou, Kexiang; Peng, Shiqi
CS College of Pharmaceutical Sciences, Peking University, Beijing, Peop. Rep. China

SO Preparative Biochemistry & Biotechnology (2004), 34(1), 57-76
CODEN: PBBIF4; ISSN: 1082-6068
PB Marcel Dekker, Inc.
DT Journal
LA English
OS CASREACT 141:81672

IT **666832-21-9P 716338-49-7P**
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(synthesis and thrombolytic activity of carboline-3-carboxylic acid modified metabolites of Ala-Arg-Pro-Ala-Lys)

RN 666832-21-9 CAPLUS
CN L-Lysine, (3S)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carbonyl-L-prolyl-L-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 716338-49-7 CAPLUS
CN L-Lysine, (3S)-2-[(1,1-dimethylethoxy)carbonyl]-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carbonyl-L-prolyl-L-alanyl-N6-[(phenylmethoxy)carbonyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN
AB This invention provides a process of liquid synthesis of fibrin degradation

product P6A derivs. The invention also provides a process of compound of P6A derivs. and carbolinecarboxylic acids. The compound can be used as antithrombics for treating coronary heart disease, brain thrombosis, myocardial infarction, cerebral embolism, lung embolism and venous thrombosis.

AN 2003:652809 CAPLUS
DN 140:231199
TI Synthesis of compounds of fibrin degradation product P6A derivatives and carbolinecarboxylic acid and their use as antithrombics
IN Peng, Shiqi; Zhao, Ming; Wang, Chao; Wu, Yanfang
PA Guangzhou Baiyunshan Pharmaceutical General Factory, Guangzhou Baiyunshan Pharmaceutical Co., Ltd., Peop. Rep. China
SO Faming Zhuanli Shenqing Gongkai Shuomingshu, 34 pp.
CODEN: CNXXEV
DT Patent
LA Chinese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI CN 1373139	A	20021009	CN 2002-100424	20020128
PRAI CN 2002-100424		20020128		

IT **666832-04-8P 666832-21-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(synthesis of compds. of fibrin degradation product P6A derivs. and carbolinecarboxylic acid and their use as antithrombics)
RN 666832-04-8 CAPLUS
CN L-Lysine, (3S)-2-[(1,1-dimethylethoxy)carbonyl]-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carbonyl-L-prolyl-L-alanyl-N6-[[(2-chlorophenyl)methoxy]carbonyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





RN 666832-21-9 CAPLUS
CN L-Lysine, (3S)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carbonyl-L-prolyl-L-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN
GI



I



II

AB Title compds. [I; X = aryl; Y = H, alkyl, (substituted) aralkyl, acyl, aroyl, heterocyclylcarbonyl, carbamoyl, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl; Z = (substituted) N-containing heterocyclyl, amino, amino acid residue, peptide residue, etc.; m = 0-3; n = 0-4], were prepared Thus, (3R)-2-tert-butoxycarbonyl-1,2,3,4-tetrahydro-9H-pyrido[3,4-b]indole-3-carboxylic acid in THF at -15° was treated with Et3N and N,N-bis[2-oxo-3-oxazolinyl]phosphorodiamidic chloride followed by stirring for 20 min. Benzyl N-(L-prolyl)nipecotate was added and the mixture was stirred overnight at ice temperature to give the amide, which was deprotected with CF3CO2H followed by acylation with 3,4-dichlorophenyl isocyanate and hydrogenolysis to give title compound II. II bound to CCk-A, CCK-B, and gastrin receptors with IC50's of 10, 0.111, and 0.026 μM, resp.

AN 1992:256054 CAPLUS

DN 116:256054

TI Preparation of peptide-linked 1,2,3,4-tetrahydro-9H-pyrido[3,4-b]indoles and related compounds as inhibitors of cholecystokinin and gastrin

IN Molino, Bruce F.; Darkes, Paul R.; Ewing, William R.

PA Rorer International (Holdings), Inc., USA

SO PCT Int. Appl., 94 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9200295	A1	19920109	WO 1991-US4236	19910613
	W: AU, CA, JP, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE				
	US 5162336	A	19921110	US 1990-573514	19900824
	CA 2068887	AA	19911222	CA 1991-2068887	19910613
	AU 9186116	A1	19920123	AU 1991-86116	19910613
	AU 640277	B2	19930819		
	EP 491943	A1	19920701	EP 1991-916717	19910613
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
PRAI	US 1990-542495	A	19900621		
	US 1990-573514	A2	19900824		
	WO 1991-US4236	A	19910613		

OS MARPAT 116:256054
IT **139985-19-6P 139985-36-7P 139986-23-5P**
139986-31-5P 140148-66-9P 140148-67-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of, as cholecystokinin and gastrin antagonist)
RN 139985-19-6 CAPLUS
CN L-α-Asparagine, N2-[1-[[2-[[(3,4-dichlorophenyl)amino]carbonyl]-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-3-yl]carbonyl]-L-prolyl]-, (R)- (9CI) (CA INDEX NAME)



RN 139985-36-7 CAPLUS
CN L-α-Asparagine, N2-[1-[[2,3,4,9-tetrahydro-2-[[(3-methylphenyl)amino]carbonyl]-1H-pyrido[3,4-b]indol-3-yl]carbonyl]-L-prolyl]-, (R)- (9CI) (CA INDEX NAME)



RN 139986-23-5 CAPLUS
CN Butanoic acid, 4-amino-3-[[[1-[[2-[[(3,4-dichlorophenyl)amino]carbonyl]-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-3-yl]carbonyl]-2-piperidinyl]carbonyl]amino]-4-oxo-, [3R-[3R*[S*(S*)]]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 139986-31-5 CAPLUS
CN L-α-Asparagine, N2-[1-[[2-[[(3,4-dichlorophenyl)amino]carbonyl]-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-3-yl]carbonyl]-L-prolyl]-N2-methyl-, (R)- (9CI) (CA INDEX NAME)



RN 140148-66-9 CAPLUS
CN D-α-Asparagine, N2-[1-[[2,3,4,9-tetrahydro-2-[[(3-methylphenyl)amino]carbonyl]-1H-pyrido[3,4-b]indol-3-yl]carbonyl]-D-prolyl]-, (S)- (9CI) (CA INDEX NAME)



RN 140148-67-0 CAPLUS
CN D-α-Asparagine, N2-[1-[[2-[[(3,4-dichlorophenyl)amino]carbonyl]-

2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-3-yl]carbonyl]-D-prolyl]-, (S)-
(9CI) (CA INDEX NAME)